What is bicalutamide?

Bicalutamide is a nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury. Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer.

What is LiverTox bicalutamide?

Bicalutamide is a nonsteroidal antiandrogen similar in structure to flutamidethat is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury. LiverTox Bicalutamide is only found in individuals that have used or taken this drug. It is an oral non-steroidal anti-androgen for prostate cancer.

What are the indications of bicalutamide for prostate cancer?

Bicalutamide is approved for and mainly used in the following indications: Metastatic prostate cancer (mPC) in men in combination with a gonadotropin-releasing hormone (GnRH) analogue or surgical castration at moderate doses Locally advanced prostate cancer (LAPC) in men as a monotherapy in high doses

Does bicalutamide cause liver damage?

Bicalutamide is a nonsteroidal antiandrogen similar in structure to flutamide that is used widely in the therapy of prostate cancer and has been linked to rare instances of liver injury. Bicalutamide is only found in individuals that have used or taken this drug.

It is used with a type of drug called a luteinizing hormone-releasing hormone agonist. Bicalutamide is also being studied in the treatment of other types of cancer. Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.

How many MTF are treated with bicalutamide 50 mg daily?

Results: Of 77 patients with GD identified, 29 were MTF, of whom 14 (48%) aged 15.8 ± 1.9 years (range 12-18.4yr) were treated with bicalutamide 50 mg daily between 2013 and 2017. Of these, 3 were started on estrogen concurrently whereas 11 received bicalutamide alone, 7 of whom have returned for follow up thus far.

Does bicalutamide cause feminization in MTF patients with gynecomastia?

Discussion Bicalutamide is used in rare forms of precocious puberty in boys and has a known side effect of gynecomastia. Here, we report the novel use of bicalutamide as a puberty blocker in MTF patients with GD in whom it also results in feminization by causing breast development.

Can bicalutamide be used as a puberty blocker in MTF patients with GD?

Here, we report the novel use of bicalutamide as a puberty blocker in MTF patients with GD in whom it also results in feminization by causing breast development. To our knowledge, we are the first to report the use of bicalutamide in this setting.